From Our Neurons to Yours

Welcome back to "From Our Neurons to Yours," a podcast from the Wu Tsai Neurosciences Institute at Stanford University.
In this episode, we explore the collective intelligence of ant colonies with Deborah Gordon, a professor of biology at Stanford, an expert on ant behavior, and author of a new book, The Ecology of Collective Behavior.
We discuss how ant colonies operate without centralized control, relying on simple local interactions, such as antennal contact, to coordinate their behavior. Gordon explains how studying ant colonies can provide insights into the workings of the human brain, highlighting parallels between different types of collective behavior in ants and the modular functions of the brain.
Listen to the episode to learn more about the intelligence of ant colonies and the implications for neuroscience.
Links
Dr. Gordon's research website
What ants teach us about the brain, cancer and the Internet (TED talk)
An ant colony has memories that its individual members don’t have (Aeon)
The Queen does not rule (Aeon)
Local links run the world (Aeon)
The collective wisdom of ants (Scientific American)Deborah Gordon: Why Don't Ants Need A Leader? (NPR)
What Do Ants Know That We Don't? (WIRED)
Episode Credits
This episode was produced by Michael Osborne, with production assistance by Morgan Honaker, and hosted by Nicholas Weiler. Cover art by Aimee Garza.

Send us a text!

Thanks for listening! If you're enjoying our show, please take a moment to give us a review on your podcast app of choice and share this episode with your friends. That's how we grow as a show and bring the stories of the frontiers of neuroscience to a wider audience.

Learn more about the Wu Tsai Neurosciences Institute at Stanford and follow us on Twitter, Facebook, and LinkedIn.

Welcome back to "From Our Neurons to Yours," a podcast where we criss-cross scientific disciplines to take you to the frontiers of brain science. This week, we explore the science of dizziness with Stanford Medicine neurologist Kristen Steenerson, MD, who treats patients experiencing vertigo and balance disorders.

In our conversation, we'll see that dizziness is not a singular experience but rather a broad term encompassing a variety of different sensations of disorientation. We learn about the vestibular system, a set of biological "accelerometers" located deep within the inner ear that detect linear and angular acceleration, helping us perceive motion, orientation, and our connection to the world around us.
We also discuss a wearable medical device Dr. Steenerson and colleagues at the Wu Tsai Neurosciences Institute are developing a wearable device to measure the activity of the vestibular system by tracking a patient's eye movements. With the ability to study this mysterious system in unprecedented detail, we're on the verge of learning more than ever about this misunderstood "sixth sense."
Learn More
Dr. Steenerson's Stanford academic profile
Dr. Steenerson's Stanford Healthcare profile (Neurology and Neurological Sciences, Otolaryngology)
The wearable ENG, a dizzy attack event monitor (DizzyDx)
References

Popkirov, Stoyan, Jeffrey P. Staab, and Jon Stone. "Persistent postural-perceptual dizziness (PPPD): a common, characteristic and treatable cause of chronic dizziness." Practical neurology 18.1 (2018): 5-13.
Harun, Aisha, et al. "Vestibular impairment in dementia." Otology & Neurotology: Official Publication of the American Otological Society, American Neurotology Society [and] European Academy of Otology and Neurotology 37.8 (2016): 1137.
Brandt T, Dieterich M. The dizzy patient: don't forget disorders of the central vestibular system. Nat Rev Neurol. 2017 Jun;13(6):352-362. doi: 10.1038/nrneurol.2017.58. Epub 2017 Apr 21. PMID: 28429801.
Allison S. Young, Corinna Lechner, Andrew P. Bradshaw, Hamish G. MacDougall, Deborah A. Black, G. Michael Halmagyi, Miriam S. Welgampola Neurology Jun 2019, 92 (24) e2743-e2753; DOI: 10.1212/WNL.0000000000007644
Episode Credits

This episode was produced by Michael Osborne, with production assistance by Morgan Honaker, and hosted by Nicholas Weiler. Cover art by Aimee Garza.

Send us a text!

Thanks for listening! If you're enjoying our show, please take a moment to give us a review on your podcast app of choice and share this episode with your friends. That's how we grow as a show and bring the stories of the frontiers of neuroscience to a wider audience.

Learn more about the Wu Tsai Neurosciences Institute at Stanford and follow us on Twitter, Facebook, and LinkedIn.

In the past few years, Big Pharma has released not one, but three new treatments for Alzheimer’s disease.
Aducanemab (2021), Lecanemab (2023), and Donanemab (2024), are the first treatments to effectively clear the brain of amyloid plaques — the sticky protein clumps whose build-up in the brain has defined the disease for decades. The problem? They may not help patients at all.

Today’s guest, Stanford neurologist Mike Greicius, considers the new amyloid-clearing drugs a major disappointment — and worse, says they likely do more harm than good for patients.

Despite this critique, Greicius, thinks that the next few years will be an exciting time for novel Alzheimer’s therapies, as growing biological understanding of Alzheimer’s risk and resilience bear fruit with promising new approaches to treatment.

Learn More:
Greicius is the Iqbal Farrukh and Asad Jamal Professor of Neurology and Neurological Sciences at Stanford Medicine, and a member of the Knight Initiative for Brain Resilience and Alzheimer's Disease Research Center at Stanford University.

Amyloid Drug Skepticism:

• Substantial Doubt Remains about the Efficacy of Anti-Amyloid Antibodies
  (Commentary, Journal of Alzheimer's Disease, 2024)
• New Drug Approved for Early Alzheimer’s (New York Times, 2024)
• Alzheimer's drug adoption in US slowed by doctors' skepticism (Reuters, 2024)
• One step back: Why the new Alzheimer’s plaque-attack drugs don’t work (Stanford Medicine Scope Blog, 2024)

Alzheimer's Genetics Research:

• Knight-funded research uncovers gene mutations that may prevent Alzheimer’s Disease (Knight Initiative for Brain Resilience, 2024)
• Why is a common gene variant bad for your brain? (Stanford Medicine Magazine, 2024)
• Scientists find genetic Alzheimer’s risk factor tied to African ancestry (Stanford Medicine, 2023)

Episode Credits

This episode was produced by Michael Osborne, with production assistance by Morgan Honaker, and hosted by Nicholas Weiler. Art by Aimee Garza.

Send us a text!

Thanks for listening! If you're enjoying our show, please take a moment to give us a review on your podcast app of choice and share this episode with your friends. That's how we grow as a show and bring the stories of the frontiers of neuroscience to a wider audience.

Learn more about the Wu Tsai Neurosciences Institute at Stanford and follow us on Twitter, Facebook, and LinkedIn.

Nearly one in five Americans lives with a mental illness. Unfortunately there’s a limited set of options for treating psychiatric disorders. One reason for that is that these disorders are still defined based on people’s behavior or invisible internal states — things like depressed mood or hallucinations.
But of course, all our thoughts and behaviors are governed by our brains. And there’s a lot of research that makes it clear that many disorders, including schizophrenia, autism, and probably depression, may have their origin during early-stage brain development. The problem is that we still don’t know which brain circuits specifically are responsible for these disorders — or how they got that way.
Studying human brain circuits as they develop is — obviously — challenging. But what if we could rewind the clock and follow the development of neurological circuits in real time? Believe it or not, new technologies may soon make this possible.
Today's guest is Sergiu Pasca, Kenneth T. Norris, Jr. Professor of Psychiatry and Behavioral Sciences at Stanford University School of Medicine and Bonnie Uytengsu and Family Director of the Stanford Brain Organogenesis Program at the Wu Tsai Neurosciences Institute.
Pasca and his team have developed techniques to create tiny models of a patient's brain tissue in the lab — models called brain organoids and assembloids. They can watch these models grow in lab dishes from a few cells into complex circuits. And they can even transplant them into rats to see how they integrate into a working brain.
While all this may sound like science fiction, these techniques are fueling a revolution in scientists' ability to observe human brain development in real time, trace the origins of psychiatric disorders and — hopefully — develop new treatments.
Further Reading

• Reverse engineering human brain by growing neural circuits in the lab | Wu Tsai Neuro
• Human brain cells transplanted into rat brains hold promise for neuropsychiatric research | News Center | Stanford Medicine
• Sergiu P. Pasca: How we're reverse engineering the human brain in the lab | TED Talk
• Assembloid models usher in a new era of brain science | Stanford Medicine
• Human Brains Are Hard to Study. Sergiu Paşca Grows Useful Substitutes. | Quanta Magazine

Episode Credits
This episode was produced by Michael Osborne, with product

Send us a text!

Thanks for listening! If you're enjoying our show, please take a moment to give us a review on your podcast app of choice and share this episode with your friends. That's how we grow as a show and bring the stories of the frontiers of neuroscience to a wider audience.

Learn more about the Wu Tsai Neurosciences Institute at Stanford and follow us on Twitter, Facebook, and LinkedIn.

In this episode of "From Our Neurons to Yours," we're taking a deep dive into the neuroscience of obsessive-compulsive disorder (OCD) and the recent discovery that the anesthetic ketamine can give patients a week-long "vacation" from the disorder after just one dose.
Join us as we chat with Dr. Carolyn Rodriguez, a leading expert in the field, who led the first clinical trial of Ketamine for patients with OCD. She sheds light on what OCD truly is, breaking down the misconceptions and revealing the reality of this serious condition.
Dr. Rodriguez, a professor of psychiatry at Stanford Medicine, discusses her research on ketamine for OCD, current hypotheses about how it works in the brain, and her approach to developing safer treatments. Listeners are encouraged to seek help if they or a loved one are struggling with OCD.
Learn more:

Rodriguez's OCD Research Lab (website)
Rodriguez at the World Economic Forum (video - WEF)
International OCD Foundation (IOCDF) (website)
Rodriguez pioneers VR therapy for patients with hoarding disorder (video - Stanford Medicine)
The rebirth of psychedelic medicine (article - Wu Tsai Neuro)
Researcher investigates hallucinogen as potential OCD treatment (article - Stanford Medicine)
Episode credits:

This episode was produced by Michael Osborne at 14th Street Studios, with production assistance by Morgan Honaker. Our logo is by Aimee Garza. The show is hosted by Nicholas Weiler at Stanford's Wu Tsai Neurosciences Institute.

Send us a text!

Thanks for listening! If you're enjoying our show, please take a moment to give us a review on your podcast app of choice and share this episode with your friends. That's how we grow as a show and bring the stories of the frontiers of neuroscience to a wider audience.

Learn more about the Wu Tsai Neurosciences Institute at Stanford and follow us on Twitter, Facebook, and LinkedIn.